Savara Advances MOLBREEVI Reviews in U.S., Europe, U.K.
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the European Medicines Agency has validated its marketing authorization application for MOLBREEVI, initiating a formal review of the treatment for autoimmune pulmonary …
Savara Advances MOLBREEVI Reviews in U.S., Europe, U.K. Read More